IDH2 and glioma: To test this further, a number of clinical trials are ongoing including a phase 2 trial combining nivolumab with ivosidenib in patients with advanced IDH-mutant solid tumors (NCT04056910) as well as a phase 1 trial of pembrolizumab and vorasidenib in patients with relapsed/refractory Grade 2 and 3 mIDH glioma (NCT0584622).